Enantioselective RP-UFLC Method for the Simultaneous Estimation of Sitagliptin (STG) enantiomers (R and S) in racemic mixture and their Pharmacokinetic assessment in male Wistar Rats
Abstract
The present work aims to develop and validate a simple, rapid, and reproducible reverse phase ultra-fast liquid chromatography method with a UV detector (RP-UFLC-UV) was developed for the separation and determination of sitagliptin (STG) enantiomers (S-(STG) and R-(STG)) simultaneously. Baseline separation was achieved on Lux cellulose-1 column, (cellulose tri-(3,5-dimethyl phenyl carbamate (Chiralcel OD-RH, 250 mm × 4.6 mm, 5 μm) column and mobile phase consisted of 20mM borate buffer solution (pH = 9±0.05) and ACN in the ratio of (60:40, v/v) at a flow rate of 0.8 mL/min was used. Detection of peaks was monitored at 262 nm. For analyzing the STG enantiomers in the rat serum and pure API, a method was developed using the chiral RP-UFLC-UV method was validated. The single oral dose of 2.5 mg/kg of STG racemate was administered to a group of 6 healthy rats for a comparative pharmacokinetic study of both the enantiomers. The linear range of the calibration curve for each enantiomer was 0.5–64 μg/mL. The precision of this method at concentrations between 0.5–48 μg/mL was within 8.65% and the % recovery (accuracy) of both sitagliptin (STG) enantiomers (S-(STG) and R-(STG) were 98.47–101.02% and 98.93-100.52%. The precision at LLOQ (0.5 μg/mL) was between 8.65%-7.09%, which was poor than that at QC levels, and the average extraction recovery was higher than 85% for both sitagliptin (SGT) enantiomers at QC levels, and its pharmacokinetics of enantiomers was found to be stereoselective.
Keywords:
Sitagliptin enantiomers, UFLC-UV, Lux cellulose-1(Chiralcel OD-RH), Validation, and Pharmacokinetic.DOI
https://doi.org/10.25004/IJPSDR.2022.140108References
FDA’s policy statement for the development of new stereoisomeric drugs. Chirality. 1992; 4 (5): 338-40. Available from: DOI: 10.1002/ chir.530040513. PMID: 1354468.
Wainer Irving, ed. Drug stereochemistry: analytical methods and pharmacology. Vol. 18. CRC Press, 1993.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice.2010; 87, (1):4-14. Availablefrom: DOI: 10.1016/j. diabres.2009.10.007. Epub 2009 Nov 6. PMID: 19896746.
Dunn PJ. The importance of green chemistry in-process research and development. Chemical Society Review. 2012; 21:41(4):1452- 61. DOI: 10.1039/c1cs15041c. Epub 2011 May 12. PMID: 21562677.
Desai AA.Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis. Angewandte Chemie International Edition English. 2011; 25, 50 (9):1974-6. DOI: 10.1002/anie.201007051. Epub 2011 Jan 31. PMID: 21284073.
Bouin A-S and Michael W. Quality standards of the European Pharmacopoeia. Journal of ethnopharmacology. 2014; 158: 454- 457.
Kim D Wang LP, Beconi M, Eiermann GJ, Fisher MH, He HB, Hickey GJ, Kowalchick JE, Leiting B, Lyons K, Marsilio F, McCann ME, Patel RA, Petrov A, Scapin G, Patel SB, Roy RS, Wu JK, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE. (2R)-4-Oxo-4- 3-(trif luoromethyl)-5,6-dihydro 1,2,4 triazolo 4,3-alpha p yrazin7(8H)-yl -1-(2,4,5-trifluorophenyl)butan-2- amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry. 2005; 48:141–151.
Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2003; 12 (1):87-100. Villhauer E B, Coppola GM, Hughes TW. Annu. Rep. Medicinal Chemistry. 2001; 36:191-200.
Ahrén B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and Metabalic Research. 2004; 36(11-12):867-76. DOI: 10.1055/s-2004-826178. PMID: 15655721.
Weber AE. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. Journal of Medicinal Chemistry. 2004; 12 (47, 17) :4135-41. DOI: 10.1021/ jm030628v. PMID: 15293982.
Herman GA, Stein PP, Thornberry NA, Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin. Clinical Pharmacology and Therapeutic. 2007; 81:761–767.
Kieffer TJ, Habener JL. The glucagon-like peptides. Endocrine Reviews.1999; 20:876–913.
Meier JJ, Nauck MA. Glucose-dependent insulin tropic polypeptide/ gastric inhibitory polypeptide. Practice and Research Clinical Endocrinology and Metabolism. 2004; 18:587–606.
Zeng W, Musson DG, Fisher AL, Wang AQ. Determination of MK-0431 in human plasma using high turbulence liquid chromatography online extraction and tandem mass spectrometry. Rapid Communications in Mass Spectrometry. 2006; 20:1169–1175.
Zeng W, Musson DG, Fisher AL, Chen L, Schwartz MS, Woolf EJ, Wang AQ. Determination of sitagliptin in human urine and hemodialysate using turbulent flow online extraction and tandem mass spectrometry. Journal Pharmaceutical Biomedical Analysis. 2008; 46:534-542.
Nirogi R, Kandikere V, Mudigonda K, Komarneni P, Aleti R, Boggavarapu R. Sensitive liquid chromatography-tandem mass spectrometry method for the quantification of sitagliptin, a DPP-4 inhibitor, in human plasma using liquid-liquid extraction. Biomedical Chromatography. 2008; 22:214–222.
Zeng W, X u Y, Constanzer M, Woolf EJ. Determination of sitagliptin in human plasma using protein precipitation and tandem mass spectrometry. Journal of Chromatography B. 2010; 878:1817–1823.
Rao RN, Maurya PK, Khalid S. Development of a molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine. Talanta. 2011; 85: 950–957.
H ess C , M usshoff F, M adea B . S imultaneous i dentification a nd validated quantification of 11 oral hypoglycemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. Analytical and Bioanalytical Chemistry. 2011; 400:33–41.
El-Bagary RI, Elkady EF, Ayoub BM. Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product. Talanta. 2011; 85:673–680.
Swales JG, Gallagher RT, Denn M, Peter RM. Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 2011; 55:544-551.
Maria GB, James RR, Yohannes T, Yuan-Qing X, Christopher JK, David QL, Shiyao X, Charles SE, Suzanne C, Donald FH, Ralph AS, Stella HV. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Duchene Muscular dystrophy. 2007; 35:525– 532.
Caglar S, Onal A, Toker S. determination of sitagliptin with f luorescamine in t ablet s and spiked ser um samples by spectrofluorimetry and a degradation study. Current Pharmaceutical Analysisl. 2012; 8:278–285.
Sahaja T, Hu WH, Zeng LL, Li H, Szente L, Noszál B, Béni S. Evaluation of the interaction between sitagliptin and cyclodextrin derivatives by capillary electrophoresis and nuclear magnetic resonance spectroscopy. Electrophoresis. 2011; 32:2648– 2654.
Nageswara Rao R, Sravana B, Ramakrishna K, Saida S, Padiya R. Precolumn o-phthalaldehyde-N-acetyl-L-cysteine derivatization followed by RP-HPLC separation and fluorescence detection of sitagliptin enantiomers in rat plasma. Chirality. 2013; 25(12): 883-9. DOI: 10.1002/chir.22229. Epub 2013 Sep 12. PMID: 24038334.
Dubey SK, Saha RN and Anand A. Enantioselective tissue distribution of ketorolac and its enantiomers in rats. Drug Research. 2015; 65: 428-431.
Volosov A, Bialer M and Yagen B. Comparative stereoselective pharmacokinetic analysis of10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia. 2000; 41:1107-1111.
Masubuchi N, Tanaka M and Yamazaki H. Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats, Chirality. 1998; 10: 747-753.
Qin F, Wang XT, Jing LJ. Bidirectional chiral inversion of trantinterol enantiomers after separate doses to rats. Chirality. 2013; 25: 934-938.
Ramesh TP, Nageswara Rao P, and Kali Suresh. Enantiomeric separation of sitagliptin by a validated chiral liquid chromatographic method. Analytical Methods. 2014; 6; 223–228.
Venkata Rami Reddy BR, Raman N, Sai Kumar B and Rambabu C. Chiral separation of sitagliptin phosphate enantiomer by HPLC using amylose based chiral stationary phase. Journal of pharmacy research. 2013; 7: 546-550.
ICH Anonymous. TopicQ2B. In: Validation of analytical methods -methodology. Geneva: IFPMA; 1996.
Ahmed A, Debby Y, Yvan M, Heyden V. Chiral separations in reversed phase liquid chromatography: Evaluation of several polysaccharide based chiral stationary phases for a separation strategy update. Journal of Chromatography A. 201; 1269:154– 167.
FDA. Guidance for industry: bioanalytical method validation. US department of health and human services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM), 2013.
Pavan Kumar D, Naga Jhansi T, Srinivas Rao G and Kumar Jain K. Method Development and Validation for Enantiomer in Sitagliptin Hydrochloride by RP-HPLC. Journal of Chemical and Pharmaceutical Research. 2017; 9(12):13-17
Published
Abstract Display: 602 
PDF Downloads: 580 
